A new Perspective published in the New England Journal of Medicine led by researchers from the Harvard Pilgrim Health Care ...
For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback